Drug Trial Radar · NCT06515990
A Study of DM005 in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Aug 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
208
Planned (sponsor's estimate)
Start
Oct 31, 2024
Primary completion
Mar 2027
Study completion Sep 2027
Sponsor
- Lead sponsor
- Doma Biopharmaceutical(Suzhou)Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 23, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to find out about the safety, efficacy, and tolerability of DM005 for patients with the advanced solid tumors. DM005 is an experimental drug which is not approved by health authorities for the treatment of advanced solid tumors. For each participant, there will be a screening period of up to 28 days, a treatment period consisting of 21-day cycles, an end of treatment (EOT) Visit (+7 days), and a Follow-up Visit at 30 days (±7 days) after the EOT Visit. Participants with advanced solid malignant tumors will be treated with DM005 on Day 1 of each cycle (every 3 weeks, Q3W). An initial dose of DM005 will be infused intravenously (IV) into each participant for approximately 60 minutes (±10) on Cycle1 Day 1. If there is no infusion-related reaction (IRR) during or after the initial dose, with the Investigator's confirmation and supervision, the subsequent dosing of DM005 in the following cycles maybe infused IV for approximately 30 minutes ( ±5). A 21-day observation period (Cycle 1) will then occur, at the end of which all relevant safety data will be reviewed.
Conditions
- Carcinoma, Non-Small-Cell Lung
- Squamous Cell Carcinoma of Head and Neck
- Solid Carcinoma
Interventions
DM005Drug
An IV infusion of DM005 will be administrated approximately 30-60 min on D1 once Q3W.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting Toxicities (DLTs) of DM005Time frame: 12 months
- Maximum tolerated dose (MTD) for DM005Time frame: 12 months
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
Henry Ford Cancer Institute
Detroit, Michigan · Recruiting
Sarah Cannon Research Institute at Mary Crowley
Dallas, Texas · Recruiting
NEXT Oncology Virginia
Fairfax, Virginia · Recruiting
Chris O'Brien Lifehouse
Camperdown, New South Wales, Australia · Recruiting
Macquarie University Hospital
North Ryde, New South Wales, Australia · Recruiting
ICON Cancer Center
South Brisbane, Queensland, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.